Actively Recruiting
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
Led by Taizhou Hospital · Updated on 2023-02-21
93
Participants Needed
4
Research Sites
391 weeks
Total Duration
On this page
Sponsors
T
Taizhou Hospital
Lead Sponsor
T
Taizhou Enze Medical Center Group
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to explore whether 18F-FDG PET/CT guided reduced-dose radiotherapy would maintain survival outcomes in nasopharyngeal carcinoma (NPC) patients.
CONDITIONS
Official Title
18F-FDG PET/CT Guided Reduced-dose Radiotherapy for Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathology confirmed nasopharyngeal squamous cell carcinoma
- Stage I-IVA (8th AJCC/UICC staging system)
- Aged 18-80 years
- Karnofsky Performance Status (KPS) of 70 or higher
- Measurable lesions on 18F-FDG PET/CT before treatment
- Hemoglobin (HGB) 90 g/L or higher, absolute neutrophil count (ANC) 1.5 x 10^9/L or higher, platelets (PLT) 80 x 10^9/L or higher
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than 2.5 times the upper limit of normal (ULN); total bilirubin (TBIL) less than 2.0 times ULN
- Creatinine clearance (CCR) 60 ml/min or higher or creatinine less than 1.5 times ULN
- Signed informed consent
- Able to comply with follow-up requirements
You will not qualify if you...
- History of previous malignancies except stage I non-melanoma skin cancer or cervical carcinoma in situ
- Age younger than 18 or older than 80 years
- Pregnant or breastfeeding
- Previous radiotherapy except for non-melanomatous skin cancers outside the planned treatment area
- Prior chemotherapy or surgery (except diagnostic procedures) to the primary tumor or lymph nodes
- Severe infections or internal diseases
- Major organ dysfunction such as decompensated heart, lung, kidney, or liver failure making surgical treatment intolerable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Taizhou Central Hospital
Taizhou, Zhejiang, China, 317000
Actively Recruiting
2
Taizhou Hospital
Taizhou, Zhejiang, China, 317000
Actively Recruiting
3
Taizhou Cancer Hospital
Taizhou, Zhejiang, China, 317500
Actively Recruiting
4
Taizhou Enze Medical Center(Group) Enze Hospital
Taizhou, Zhejiang, China, 318050
Actively Recruiting
Research Team
H
Haihua Yang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here